RE: RE: RE: RE: RE: RE: what the ....!!!
===========
When a pharma is prepared to buy the company once PRX302 is cleared for marketing int he USA, the shareholders will get to vote on the deal. Yes WP will have control, but it is WP that put up the cash to get PRX302 to that point. What is the problem with that?
WP didn't put up the cash so far. Current shareholders have. WP will put in less than we have at the time when risk is lowest but will have control. That is the problem with that.
===========
Are you suggesting that Protox become the marketer of PRX302? Is that their mandate or are they a development company? What else will Protox have suffieciently developed by mid 2012 to provide supportable valuation in a transaction?
Protox is not a manufacturer. They will have a product that other companies would love to manufacture though, and could get much better terms if they had phase 3 finished.
The second part of the question is what they will have sufficiently developed by 2012. Here is a company with a technology that is working with brain cancer and other things already. Do you understand how big this could possibly be? I see value far beyond the single product that is currently being tested. That may help with my analogy of a single cab ride verses the ownership of the cab. Phase 3 for the current product then sell the company, one ride. The technology, the cab with many rides available.
===========
With this deal I see the possibility of 200,000 bucks disappearing to take the 20 bucks. That's the problem in a nutshell.
Grant.